J&J/McNeil Completes Remediation Under Consent Decree
This article was originally published in The Tan Sheet
Executive Summary
FDA officials on Aug. 21 notified the firm that its Fort Washington, Pa., manufacturing plant is compliant with the agency’s GMP regulations for drugs.
You may also be interested in...
Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls
J&J/McNeil enter a guilty plea in federal court to a misdemeanor charge of distributing adulterated drugs and agree to pay a criminal fine of $20 million and forfeit $5 million. McNeil has submitted to FDA experts’ certifications of remediation processes being complete at its three facilities subject to a consent decree.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.